A case of clinical complete response of colorectal liver metastasis following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab

Although the survival of patients with liver metastases was previously extremely poor, the introduction of novel chemotherapeutic agents, such as oxaliplatin, has increased the median survival of these patients. S-1 has been reported to show strong antitumor activity in various types of cancer, such...

Full description

Saved in:
Bibliographic Details
Published inAnnals of Cancer Research and Therapy Vol. 26; no. 2; pp. 101 - 104
Main Authors Azuhata, Takeo, Shibata, Masahiko, Nakamura, Kazuhiro, Kawano, Daisuke, Terakado, Yoshinori, Azuhata, Izumi, Sakurai, Atsushi, Yamada, Takeshi, Sugita, Kyouichi, Tomita, Ryouichi, Tsuyama, Yoshiro, Tanjoh, Katsuhisa, Azuhata, Setsuo
Format Journal Article
LanguageEnglish
Published Tokyo The Japanese Society of Strategies for Cancer Research and Therapy 21.08.2018
Japan Science and Technology Agency
Subjects
Antitumor activity
Bevacizumab
Chemotherapy
colorectal cancer
Colorectal carcinoma
Complete response
Computed tomography
Immunotherapy
Liver
liver metastases
Metastases
Metastasis
Monoclonal antibodies
Oxaliplatin
Patients
SOX
Survival
Targeted cancer therapy
Online AccessGet full text

Cover

More Information
Summary:Although the survival of patients with liver metastases was previously extremely poor, the introduction of novel chemotherapeutic agents, such as oxaliplatin, has increased the median survival of these patients. S-1 has been reported to show strong antitumor activity in various types of cancer, such as colorectal cancer (CRC), and its feasibility in combination with oxaliplatin (SOX) has been reported to have a promising efficacy with fair tolerability in patients with metastatic CRC. We here present a case of synchronous liver metastasis of CRC in which a complete clinical response was successfully achieved by SOX plus bevacizumab (BV). CT scan results confirmed a clinical complete response after eight cycles, and monotherapy with S-1 was ongoing for 6 months. Currently, there was no evidence of any recurrent or metastatic lesions. We found that a regimen of SOX plus BV is a safe and effective treatment for metastatic CRC that does not require central venous access.
ISSN:1344-6835
1880-5469
DOI:10.4993/acrt.26.101